In summary, our results indicated that MTA1 promotes NSCLC cell EMT by activating AKT/GSK3β/β-catenin signaling, indicating that MTA1 is a potential anti-NSCLC therapeutic target. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.